Differences in technical and clinical perspectives on AI validation in cancer imaging: mind the gap!

Journal: European radiology experimental
Published Date:

Abstract

Good practices in artificial intelligence (AI) model validation are key for achieving trustworthy AI. Within the cancer imaging domain, attracting the attention of clinical and technical AI enthusiasts, this work discusses current gaps in AI validation strategies, examining existing practices that are common or variable across technical groups (TGs) and clinical groups (CGs). The work is based on a set of structured questions encompassing several AI validation topics, addressed to professionals working in AI for medical imaging. A total of 49 responses were obtained and analysed to identify trends and patterns. While TGs valued transparency and traceability the most, CGs pointed out the importance of explainability. Among the topics where TGs may benefit from further exposure are stability and robustness checks, and mitigation of fairness issues. On the other hand, CGs seemed more reluctant towards synthetic data for validation and would benefit from exposure to cross-validation techniques, or segmentation metrics. Topics emerging from the open questions were utility, capability, adoption and trustworthiness. These findings on current trends in AI validation strategies may guide the creation of guidelines necessary for training the next generation of professionals working with AI in healthcare and contribute to bridging any technical-clinical gap in AI validation. RELEVANCE STATEMENT: This study recognised current gaps in understanding and applying AI validation strategies in cancer imaging and helped promote trust and adoption for interdisciplinary teams of technical and clinical researchers. KEY POINTS: Clinical and technical researchers emphasise interpretability, external validation with diverse data, and bias awareness in AI validation for cancer imaging. In cancer imaging AI research, clinical researchers prioritise explainability, while technical researchers focus on transparency and traceability, and see potential in synthetic datasets. Researchers advocate for greater homogenisation of AI validation practices in cancer imaging.

Authors

  • Ioanna Chouvarda
  • Sara Colantonio
    Institute of Information Science and Technologies - ISTI of the National Research Council - CNR, Pisa, Italy.
  • Ana S C Verde
    Computational Clinical Imaging Group (CCIG), Champalimaud Research, Champalimaud Foundation, Lisbon, Portugal.
  • Ana Jimenez-Pastor
    QUIBIM SL, Valencia, Spain. anajimenez@quibim.com.
  • Leonor Cerdá-Alberich
    Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, Av. Fernando Abril Martorell 106, Torre E, 46026, Valencia, Spain.
  • Yannick Metz
    Data Analysis and Visualization, University of Konstanz, Konstanz, Germany.
  • Lithin Zacharias
    School of Life Sciences, Pharmacy and Chemistry, Kingston University London, Kingston upon Thames, United Kingdom.
  • Shereen Nabhani-Gebara
    Faculty of Health, Science, Social Care & Education, Kingston University London, London, UK.
  • Maciej Bobowicz
    2nd Department of Radiology, Medical University of Gdansk, Gdansk, Poland.
  • Gianna Tsakou
    MAGGIOLI S.P.A., Research and Development Lab, Marousi, Greece.
  • Karim Lekadir
    Information and Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain.
  • Manolis Tsiknakis
    Computational BioMedicine Laboratory, FORTH-ICS, Heraklion, Crete, Greece.
  • Luis Marti-Bonmati
    QUIBIM SL, Valencia, Spain.
  • Nikolaos Papanikolaou
    Computational Biomedicine Laboratory (CBML), Foundation for Research and Technology Hellas (FORTH), 70013 Heraklion, Greece.